This article was originally published in The Gray Sheet
Plans an offering of $2.3 mil. in units, each consisting of convertible preferred stock and common stock purchase warrants. Proceeds from the offering are slated for increased marketing efforts for the Sacramento, California-based company's in vitro diagnostic test kits
You may also be interested in...
Among four FDA regulatory items withdrawn from OMB review is “Cannabidiol Enforcement Policy; Draft Guidance for Industry,” which the agency submitted in July 2020.
A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.